Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Blaise D"'
Autor:
Sanz, Jaime, Galimard, J.E., Labopin, M., Afanasyev, B., Angelucci, E., Ciceri, F., Blaise, D., Cornelissen, J.J., Meijer, E., Diez-Martin, J.L., Koc, Y., Rovira Tarrats, Montserrat, Castagna, L., Savani, B.N, Ruggeri, A., Nagler, A., Mohty, M., Universitat Autònoma de Barcelona
Publikováno v:
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Journal of hematology & oncology, 13(1):46. BioMed Central
JOURNAL OF HEMATOLOGY & ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-13 (2020)
Sanz, J, Galimard, J E, Labopin, M, Afanasyev, B, Angelucci, E, Ciceri, F, Blaise, D, Cornelissen, J J, Meijer, E, Diez-Martin, J L, Koc, Y, Rovira, M, Castagna, L, Savani, B, Ruggeri, A, Nagler, A, Mohty, M & Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) 2020, ' Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia : a comparative study of the ALWP EBMT ', Journal of hematology & oncology, vol. 13, no. 1, 46 . https://doi.org/10.1186/s13045-020-00882-6
Journal of Hematology & Oncology
Journal of Hematology & Oncology, 13(1):46. BioMed Central Ltd.
Universitat Autònoma de Barcelona
Journal of hematology & oncology, 13(1):46. BioMed Central
JOURNAL OF HEMATOLOGY & ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-13 (2020)
Sanz, J, Galimard, J E, Labopin, M, Afanasyev, B, Angelucci, E, Ciceri, F, Blaise, D, Cornelissen, J J, Meijer, E, Diez-Martin, J L, Koc, Y, Rovira, M, Castagna, L, Savani, B, Ruggeri, A, Nagler, A, Mohty, M & Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) 2020, ' Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia : a comparative study of the ALWP EBMT ', Journal of hematology & oncology, vol. 13, no. 1, 46 . https://doi.org/10.1186/s13045-020-00882-6
Journal of Hematology & Oncology
Journal of Hematology & Oncology, 13(1):46. BioMed Central Ltd.
BackgroundThe use of post-transplant cyclophosphamide (PTCy) is highly effective in preventing graft-versus-host disease (GVHD) in the haploidentical (Haplo) transplant setting and is being increasingly used in matched sibling (MSD) and matched unrel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6219eb6b70b04985a207e70bdde2ae04
https://ddd.uab.cat/record/236424
https://ddd.uab.cat/record/236424
Autor:
Passweg, J.R., Labopin, M., Cornelissen, J., Volin, L., Socie, G., Huynh, A., Tabrizi, R., Wu, D., Craddock, C., Schaap, N.P., Kuball, J., Chevallier, P., Cahn, J.Y., Blaise, D., Ghavamzadeh, A., Bilger, K., Ciceri, F., Schmid, C., Giebel, S., Nagler, A., Mohty, M.
Publikováno v:
Bone Marrow Transplantation, 50, 1063-8
Bone Marrow Transplantation, 50(8), 1063-1068. Nature Publishing Group
Bone Marrow Transplantation, 50, 8, pp. 1063-8
Bone Marrow Transplantation, 50(8), 1063. Nature Publishing Group
Bone Marrow Transplantation, 50(8), 1063-1068. Nature Publishing Group
Bone Marrow Transplantation, 50, 8, pp. 1063-8
Bone Marrow Transplantation, 50(8), 1063. Nature Publishing Group
Contains fulltext : 152063.pdf (Publisher’s version ) (Closed access) In recipients of allogeneic hematopoietic stem cell transplantation with AML in CR1, reduced intensity (RIC) conditioning regimens are usually given to older patients and myeloab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f6641137b10f355dbe67461606302e9
http://hdl.handle.net/2066/152063
http://hdl.handle.net/2066/152063
Autor:
Garderet, L., Labopin, M., Gorin, N. C., Polge, E., Baruchel, A., Meloni, Giovanna, Ortega, J., Vossen, J., Bunjes, D., Leverger, G., Blaise, D., Ferrant, A., Brune, M., Dore, E., Gadner, H., Zintl, F., Yaniv, I., Dini, G., Frassoni, F., Leukemia Working Party Acute, The European Group For Blood, Pediatric Working Party O. F., Transplantation, Marrow
Acute megakaryoblastic leukemia (M7 AML) is a highly aggressive disease. We evaluated outcomes in 57 children (11 with Down syndrome) and 69 adults with M7 AML after first complete remission (CR1) following autologous or HLA-identical allogeneic tran
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33dd5bcb29d4c32ce864b5aacfd23a6c
http://hdl.handle.net/11573/89525
http://hdl.handle.net/11573/89525
Autor:
Matthias Edinger, Arnold Ganser, Annalisa Ruggeri, Martin Gramatzki, Arnon Nagler, Myriam Labopin, Patrice Chevallier, Nicolaus Kröger, Eolia Brissot, Didier Blaise, Bipin N. Savani, Fabio Ciceri, Jürgen Finke, Mohamed A. Kharfan-Dabaja, Jaime Sanz, Matthias Stelljes, Eric Deconinck, Mohamad Mohty
Publikováno v:
BRITISH JOURNAL OF HAEMATOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
British Journal of Haematology
British Journal of Haematology, 2021, 193 (3), pp.592-601. ⟨10.1111/bjh.17426⟩
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
British Journal of Haematology
British Journal of Haematology, 2021, 193 (3), pp.592-601. ⟨10.1111/bjh.17426⟩
Optimal donor choice for a second allogeneic haematopoietic cell transplant (allo-HCT) in relapsed acute myeloid leukaemia (AML) remains unknown. We compared overall survival (OS) using registry data from the Acute Leukemia Working Party (ALWP) of th
Autor:
Ali Bazarbachi, Yener Koc, Concepcion Herrera, Luca de Rosa, Mutlu Arat, Rocco Pastano, Hakan Ozdogu, Mohamad Mohty, Paolo Bernasconi, Didier Blaise, Célestine Simand, Luca Castagna, J. L. Diez-Martin, Myriam Labopin, Antonin Vitek, Rovira Montserrat, Giuseppe Marotta, Gérard Socié, Eolia Brissot, Fabio Ciceri, Emanuele Angelucci, Andrew M. McDonald, Zafer Gulbas, Guiseppe Visani, Pietro Pioltelli, Arnon Nagler, Wolf Rösler, Sebastian Giebel, Yves Chalandon, Paola Carluccio, Boris V. Afanasyev, Massimo Martino
Publikováno v:
Biology of Blood and Marrow Transplantation, Vol. 26, No 5 (2020) pp. 936-942
Biology of Blood and Marrow Transplantation
Biology of Blood and Marrow Transplantation, Elsevier, 2020, 26 (5), pp.936-942. ⟨10.1016/j.bbmt.2020.01.003⟩
Biology of Blood and Marrow Transplantation, 2020, 26 (5), pp.936-942. ⟨10.1016/j.bbmt.2020.01.003⟩
Biology of Blood and Marrow Transplantation
Biology of Blood and Marrow Transplantation, Elsevier, 2020, 26 (5), pp.936-942. ⟨10.1016/j.bbmt.2020.01.003⟩
Biology of Blood and Marrow Transplantation, 2020, 26 (5), pp.936-942. ⟨10.1016/j.bbmt.2020.01.003⟩
Allogeneic hematopoietic cell transplantation (HCT) is recommended in high-risk patients with T cell acute lymphoblastic leukemia (T-ALL). For patients without an HLA-identical donor, haploidentical (haplo-) HCT is becoming the leading source of stem
Autor:
Jaime Sanz, Patrice Ceballos, Fabio Ciceri, Hélène Labussière-Wallet, Ludmila S. Zubarovskaya, Frédéric Baron, Edouard Forcade, Mohamad Mohty, Jan J. Cornelissen, Bhagirathbhai Dholaria, Jürgen Kuball, Anna De Grassi, Annalisa Ruggeri, Myriam Labopin, Didier Blaise, Arnon Nagler, Patrice Chevallier, Bipin N. Savani
Publikováno v:
JOURNAL OF HEMATOLOGY & ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Journal of Hematology & Oncology
Journal of Hematology & Oncology, 2021, 14 (1), pp.76. ⟨10.1186/s13045-021-01086-2⟩
Journal of Hematology and Oncology, 14(1):76. BioMed Central Ltd.
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-11 (2021)
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Journal of Hematology & Oncology
Journal of Hematology & Oncology, 2021, 14 (1), pp.76. ⟨10.1186/s13045-021-01086-2⟩
Journal of Hematology and Oncology, 14(1):76. BioMed Central Ltd.
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-11 (2021)
Background Allogeneic hematopoietic cell transplantation (allo-HCT) using a mismatched unrelated donor (MMUD) and cord blood transplantation (CBT) are valid alternatives for patients without a fully human leukocyte antigen (HLA)-matched donor. Here,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d85c63b491734d76b80ca928e704cf54
Autor:
Johanna Tischer, Arne Brecht, Tobias Gedde-Dahl, Thomas Valerius, Eolia Brissot, Didier Blaise, Mohamad Mohty, Mohamed A. Kharfan-Dabaja, Bipin N. Savani, Arnon Nagler, Jürgen Kuball, Annalisa Ruggeri, José Luis Díez-Martín, Fabio Benedetti, Tsila Zuckerman, Emanuele Angelucci, Christoph Schmid, Sebastian Giebel, Hélène Labussière-Wallet, Dolores Caballero, Martin Bornhäuser, Jaime Sanz, Victoria T Potter, Ali Bazarbachi, Benedetto Bruno, Myriam Labopin, Fabio Ciceri, Jürgen Finke, Riitta Niittyvuopio
Publikováno v:
BONE MARROW TRANSPLANTATION
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Bone Marrow Transplantation
Bone Marrow Transplantation, 2021, 56 (9), pp.2194-2202. ⟨10.1038/s41409-021-01317-7⟩
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Bone Marrow Transplantation
Bone Marrow Transplantation, 2021, 56 (9), pp.2194-2202. ⟨10.1038/s41409-021-01317-7⟩
Optimal donor choice for a second allogeneic hematopoietic cell transplant (allo-HCT) in relapsed acute lymphoblastic leukemia (ALL) remains undefined. We compared outcomes using HLA-matched unrelated donors (MUD) versus haploidentical donors in this
Autor:
Yener Koc, Veronique Leblond, Myriam Labopin, Gérard Socié, Arnon Nagler, Francesco Lanza, Norbert Claude Gorin, Eric Deconinck, Enrico Maffini, Fabio Ciceri, Didier Blaise, Bipin N. Savani, Patrick Chevallier, Mohamad Mohty, Mercedes Colorado Araujo, Zafer Gulbas
Publikováno v:
American journal of hematologyREFERENCES. 95(8)
Previous observations have reported controversial conclusions regarding cell dose and survival endpoints after allogeneic hematopoietic stem cell transplantation (HSCT). We conducted a retrospective analysis on 414 adult patients (median age 54 years
Autor:
Myriam Labopin, Gérard Socié, Fabio Ciceri, Didier Blaise, Jean Bourhis, Marco R. de Groot, Mohamad Mohty, Arnon Nagler, Emmanuelle Polge, Gorin Nc
Publikováno v:
Cancer
Cancer, Wiley, 2019, 126 (5), pp.1004-1015. ⟨10.1002/cncr.32629⟩
Cancer, 126(5), 1004-1015. Wiley
Cancer, 2019, 126 (5), pp.1004-1015. ⟨10.1002/cncr.32629⟩
Cancer, Wiley, 2019, 126 (5), pp.1004-1015. ⟨10.1002/cncr.32629⟩
Cancer, 126(5), 1004-1015. Wiley
Cancer, 2019, 126 (5), pp.1004-1015. ⟨10.1002/cncr.32629⟩
Background: In adult patients with acute myeloid leukemia (AML), a matched sibling donor (MSD) is considered the first choice for an allogeneic transplantation. However, a female donor for a male recipient is a poor prognostic factor. The authors com
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfc20cc9e81f2754ded5e7c87802a134
Autor:
Massimo F. Martelli, Piyanuch Kongtim, Paul O'Donnell, Monzr M. Al Malki, Philippe Lewalle, Rupert Handgretinger, Jorge Gayoso, Michael Maschan, Christoph Schmid, Norbert Claude Gorin, Andrea Bacigalupo, Denis-Claude Roy, Karen K. Ballen, Hillard M. Lazarus, Arnon Nagler, Myriam Labopin, Stephan Mielke, Alexandros Spyridonidis, Fabio Ciceri, A. Ruggeri, Asad Bashey, Yolande Arnault, Stefan O. Ciurea, Leo Luznik, Sebastian Giebel, Frédéric Baron, Mohamad Mohty, Ephraim J. Fuchs, Bipin N. Savani, Scott D. Solomon, Bhagirathbhai Dholaria, Franco Aversa, Xiao-Jun Huang, Didier Blaise, Franco Locatelli, Luca Castagna, Jordi Esteve, Patrick Ben Soussan, Rizwan Romee
Publikováno v:
Haematologica
Haematologica, vol 105, iss 1
Haematologica, 105 (1
Haematologica, vol 105, iss 1
Haematologica, 105 (1
Donor lymphocyte infusion has been used in the management of relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. It can eradicate minimal residual disease or be used to rescue a hematologic relapse, being able to in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff7e197a985ab07c7744c121d8edac5e
http://hdl.handle.net/11573/1480344
http://hdl.handle.net/11573/1480344